Economic Rules Hub
  • World
  • Politics
  • Business
  • Investing
Home Business Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers
Business

Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers

by admin June 29, 2024
June 29, 2024

The Biden administration on Wednesday said it will impose inflation penalties on 64 prescription drugs for the third quarter of this year, lowering costs for certain older Americans enrolled in Medicare. 

President Joe Biden has made lowering U.S. drug prices a key pillar of his health-care agenda and reelection platform for 2024. A provision of Biden’s Inflation Reduction Act requires drugmakers to pay rebates to Medicare, the federal health program for Americans over age 65, if they hike the price of a medication faster than the rate of inflation. 

It is separate from another provision under the law that allows Medicare to negotiate lower prescription drug prices with manufacturers. On average, Americans pay two to three times more than patients in other developed nations for prescription drugs, according to the Biden administration.

Some patients will pay a lower coinsurance rate for the 64 drugs covered under Wednesday’s announcement, which fall under Medicare Part B, for the period from July 1 to Sept. 30 “since each drug company raised prices faster than the rate of inflation,” according to a release from the administration.

Some Medicare Part B patients may save as much as $4,593 per day if they use those drugs during the quarter, the release added.  

More than 750,000 Medicare patients use the drugs each year, according to the release. The medications treat conditions such as cancer, certain infections and a bone disease called osteoporosis.

“Without the Inflation Reduction Act, seniors were completely exposed to Big Pharma’s price hikes. Not anymore,” Neera Tanden, White House domestic policy advisor, said in the release.

The Centers for Medicare & Medicaid Services plans to send the first invoices to drugmakers in 2025 for the rebates owed to the program.

In December, Biden released a list of 48 prescription drugs that would be subject to inflation penalties during the first quarter of 2024.

This post appeared first on NBC NEWS

0
FacebookTwitterPinterestEmail
previous post
France is set for its most consequential election in decades. Here’s what you need to know
next post
YouTube is dominating the living room, forcing media companies to decide whether it’s friend or foe

Related Posts

United Airlines reaches ‘industry-leading’ labor deal with flight attendants, union...

May 24, 2025

FTC drops Biden-era suit accusing Pepsi of price discrimination

May 24, 2025

Trump clears Nippon merger with U.S. Steel

May 24, 2025

How UnitedHealthcare became the face of America’s health insurance frustrations

May 23, 2025

Burger King targets families through movie partnerships in latest stage...

May 23, 2025

Armenian organized crime rings charged with stealing $83 million in...

May 23, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • At least 12 injured in hot air balloon crash in Mexico

      May 24, 2025
    • Several people sustain ‘life-threatening’ injuries in knife attack at Hamburg’s Central Station, police say

      May 24, 2025
    • ‘What was that bang?’ Footage captures sound of Titan sub’s implosion

      May 24, 2025
    • We’re ‘poker chips’: International Harvard students describe fear after Trump administration moves to revoke their enrollment

      May 24, 2025
    • Mexican singer Julion Alvarez postpones Texas show after US visa allegedly revoked

      May 24, 2025

    Categories

    • Business (1,371)
    • Investing (3,303)
    • Politics (4,439)
    • World (4,347)
    • Email Whitelisting
    • Terms and Conditions
    • Privacy Policy
    • Contacts
    • About us

    Disclaimer: EconomicRulesHub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 EconomicRulesHub.com | All Rights Reserved

    Economic Rules Hub
    • World
    • Politics
    • Business
    • Investing